These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37236167)

  • 41. Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Galli E; Sorà F; Hohaus S; Bellesi S; Autore F; Metafuni E; Innocenti I; Marra J; Fresa A; Limongiello MA; Giammarco S; Leccisotti L; Guarneri A; Chiusolo P; Laurenti L; Teofili L; Piccirillo N; Bacigalupo A; Sica S
    Bone Marrow Transplant; 2022 May; 57(5):837-839. PubMed ID: 35260803
    [No Abstract]   [Full Text] [Related]  

  • 42. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
    Sun Z; Xie C; Liu H; Yuan X
    Front Immunol; 2022; 13():778192. PubMed ID: 35154102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
    Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
    El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D
    Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546
    [No Abstract]   [Full Text] [Related]  

  • 46. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.
    Zhang H; Liu M; Li Q; Lyu C; Jiang YY; Meng JX; Li JY; Deng Q
    Leuk Lymphoma; 2022 Feb; 63(2):353-361. PubMed ID: 34587859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
    Di Rocco A; Cuneo A; Di Rocco A; Merli F; De Luca G; Petrucci L; Ansuinelli M; Penna D; Rotondo F; Rigolin GM; Giaimo M; Re F; Farcomeni A; Martelli M; Foà R
    Leuk Lymphoma; 2021 Apr; 62(4):828-836. PubMed ID: 33274677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
    Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
    N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.
    Chong EA; Ruella M; Schuster SJ;
    N Engl J Med; 2021 Feb; 384(7):673-674. PubMed ID: 33596362
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
    Dreger P; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner E; Wulf G; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Schroers R; Wolff D; Thomas S; Kröger N; Bethge WA; ;
    Bone Marrow Transplant; 2023 Feb; 58(2):229-232. PubMed ID: 36418916
    [No Abstract]   [Full Text] [Related]  

  • 53. Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target.
    Yamshon S; Jing-Mei H
    Leuk Lymphoma; 2022 Sep; 63(9):2019-2020. PubMed ID: 35821624
    [No Abstract]   [Full Text] [Related]  

  • 54. CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma.
    Buchtele N; Wohlfarth P; Staudinger T; Schellongowski P; Traby L; Vossen M; Knaus H; Lobmeyr E; Rabitsch W; Worel N; Staber PB
    Ann Hematol; 2023 Jan; 102(1):231-234. PubMed ID: 36399193
    [No Abstract]   [Full Text] [Related]  

  • 55. Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
    Bajwa A; Huang Y; Li R; Denlinger N; Brammer J; Penza S; Saad A; Jaglowski S; Kittai AS
    Leuk Lymphoma; 2022 Jun; 63(6):1492-1495. PubMed ID: 35109749
    [No Abstract]   [Full Text] [Related]  

  • 56. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.
    Cliff ERS; Merryman RW; Armand P; Jacobson CA
    Nat Med; 2022 Dec; 28(12):2458-2459. PubMed ID: 36348063
    [No Abstract]   [Full Text] [Related]  

  • 57. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
    Chen HH; Kuo CY; Ho CL; Chen YC
    Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights.
    Ali A; Goy A; Dunleavy K
    Blood; 2022 Sep; 140(13):1461-1469. PubMed ID: 35560330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
    Br J Haematol; 2023 Jan; 200(1):e4-e5. PubMed ID: 36281746
    [No Abstract]   [Full Text] [Related]  

  • 60. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
    Dickinson MJ; Barba P; Jäger U; Shah NN; Blaise D; Briones J; Shune L; Boissel N; Bondanza A; Mariconti L; Marchal AL; Quinn DS; Yang J; Price A; Sohoni A; Treanor LM; Orlando EJ; Mataraza J; Davis J; Lu D; Zhu X; Engels B; Moutouh-de Parseval L; Brogdon JL; Moschetta M; Flinn IW
    Cancer Discov; 2023 Sep; 13(9):1982-1997. PubMed ID: 37249512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.